Somatostatin for injection

1. It can inhibit the secretion of growth hormone, thyroid stimulating hormone, insulin, and glucagon; 2. It can inhibit the secretion of gastric acid stimulated by the test meal and pentagastrin, and inhibit the release of pepsin and gastrin; 3. It can significantly reduce visceral blood flow, reduce portal vein pressure, reduce collateral circulation blood flow and pressure, and reduce liver blood flow; 4. It can reduce the endocrine secretion of the pancreas, the secretion of the stomach, small intestine, and gallbladder, reduce enzyme activity, and have a protective effect on pancreatic cells; 5. It can inhibit the secretion of glucagon; 6. It can affect gastrointestinal absorption and nutritional function.

The main ingredients of this product and its chemical name are: Somatostatin acetate Molecular formula: C76H104N18O19S2 Molecular weight: 1638.

Severe acute esophageal varicose bleeding. Severe acute gastric or duodenal ulcer bleeding, or complicated by acute erosive gastritis or hemorrhagic gastritis. Adjuvant treatment of pancreatic, biliary and intestinal fistulas. Prevention and treatment of complications after pancreatic surgery. Adjuvant treatment of diabetic ketoacidosis.

The lyophilized powder must be dissolved in saline before use. Stamista is administered intravenously, either by slow bolus injection (3 to 5 minutes) of 250 micrograms or by continuous drip at a rate of 250 micrograms per hour (equivalent to approximately 3.5 micrograms per kilogram of body weight per hour). For continuous drip administration, a 3 mg vial of Stamista is used to prepare a 12-hour supply of solution, the solvent of which can be either saline or 5% glucose solution. The infusion volume should be adjusted to 250 micrograms per hour, and an infusion syringe is recommended. For the treatment of severe acute upper gastrointestinal bleeding (including esophageal variceal bleeding): It is recommended to first slowly inject 250 micrograms of Stamista as a loading dose, followed immediately by an intravenous drip of 250 micrograms per hour. When the interval between two infusions is greater than 3 to 5 minutes, 250 micrograms of Stamista should be reinjected intravenously to ensure continuity of administration. When the bleeding is stopped (usually within 12 to 24 hours), treatment should be continued for 48 to 72 hours to prevent recurrence. For the above cases, the usual treatment duration is 120 hours. For adjunctive treatment of pancreatic fistula, biliary fistula, and intestinal fistula: Continuous intravenous drip at a rate of 250 micrograms per hour should be used until the fistula is closed (2 to 20 days). This treatment can be used as an adjunct to total parenteral nutrition. When the fistula is closed, intravenous drip of silamin should be continued for 1 to 3 days, and then gradually discontinued to prevent rebound effect. Prevention and treatment of complications after pancreatic surgery: At the beginning of the operation, as an adjunctive treatment, silamin is dripped at a rate of 250 micrograms per hour; after the operation, the drip is continued for 5 days. Adjunctive treatment of diabetic ketoacidosis: For patients with ketoacidosis, intravenous drip of silamin at a rate of 100 to 500 micrograms per hour combined with insulin treatment can relieve ketoacidosis within 3 hours and restore blood sugar to normal within 4 hours.

A few cases experienced nausea, dizziness, blushing, etc. When the infusion rate of silamin was higher than 50 micrograms per minute, the patient would experience nausea and vomiting.

Patients with confirmed allergies to silafenamide should not use this drug. Pregnant women should avoid using this product unless there is no other safe alternative.

Precautions during pregnancy and lactation: Avoid using this product by pregnant women unless there are no other safe alternatives.

Since silatin can prolong the sleep time caused by cyclohexene barbiturate and intensify the effect of pentylene tetrazole, silatin should not be used simultaneously with such drugs or drugs with the same effect. The incompatibility of this product with other drugs has not been tested, so it should be used alone when injected or dripped.

This product should be stored in a dark and dry place below 25°C.

3 mg